| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
As a valine analogue and N-methylated amino acid derivative, N-Methyl-L-valine does not have a defined primary biological target as a standalone compound. Its primary role is as a building block in peptide synthesis and protein engineering. When incorporated into peptides, N-methylation can significantly alter the biological activity, receptor binding affinity, and metabolic stability of the resulting peptide by introducing steric constraints and modifying hydrogen bonding capabilities. The methyl group on the nitrogen atom can influence peptide conformation and resistance to proteolytic degradation.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
As a valine analogue and amino acid derivative, N-Methyl-L-valine has been studied in the context of amino acid and amino acid derivative research. Amino acids and their derivatives have been commercially used as ergogenic supplements, affecting the release of anabolic hormones, the availability of fuel for activity, mental performance under stress, and the prevention of exercise-induced muscle damage. They are regarded as advantageous synergistic food ingredients. The N-methylation introduces specific structural constraints that can modulate peptide conformation and biological activity when incorporated into peptides. |
| ln Vivo |
Specific in vivo activity data for N-Methyl-L-valine as a standalone compound are not documented in the literature. As an amino acid building block for peptide synthesis, its in vivo effects are determined by the final peptide construct into which it is incorporated. N-Methylation of amino acids in peptides is known to enhance proteolytic stability and modulate bioavailability, as the methyl group can protect the peptide bond from enzymatic cleavage. The compound's role in protein engineering allows researchers to investigate how methylation affects protein folding, function, or stability in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-Methyl-L-valine typically involve its use as a building block in peptide synthesis rather than direct binding evaluation. When incorporated into peptides, the resulting N-methylated peptides can be assessed for target binding affinity using standard biochemical assays such as radioligand binding, fluorescence polarization, or surface plasmon resonance (SPR). The N-methyl group can significantly alter the binding affinity and selectivity of peptides by introducing steric constraints and modifying hydrogen bonding interactions. Typical assay conditions include buffered solutions at physiological pH.
|
| Cell Assay |
In vitro cell-based studies using N-Methyl-L-valine typically focus on the biological activities of peptides synthesized with this building block rather than the compound itself. When incorporated into peptides, the resulting N-methylated constructs can be evaluated in various cell-based assays including cell viability assays (e.g., MTT), receptor binding and internalization studies, and functional readouts such as calcium flux, reporter gene activation, or cytokine secretion. N-methylation can enhance peptide stability in cell culture by protecting against proteolytic degradation. Standard cell culture conditions (37°C, 5% CO₂) with appropriate cell lines are employed.
|
| Animal Protocol |
In vivo animal studies using N-Methyl-L-valine are conducted with peptides synthesized from this building block rather than the compound itself. Typical experimental designs involve administration of the N-methylated peptide construct to rodent models (e.g., mice or rats) via appropriate routes. The N-methyl group can enhance peptide stability and prolong circulation half-life by protecting against proteolytic degradation. Endpoints may include efficacy measurements (e.g., tumor growth inhibition, biomarker modulation), pharmacokinetic sampling, and toxicological assessments. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for N-Methyl-L-valine as a standalone compound are not well characterized. The compound is highly water-soluble, with solubility in H₂O at 100 mg/mL (762.37 mM). It has a molecular weight of 131.17 g/mol and is typically stored as a powder at -20°C (stable for 3 years) or 4°C (stable for 2 years); in solvent, it can be stored at -80°C for 6 months or -20°C for 1 month. When incorporated into peptides, the pharmacokinetic properties are determined by the overall peptide construct. N-methylation can enhance peptide stability and prolong half-life by protecting against proteolytic degradation.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-Methyl-L-valine as a standalone compound are not extensively documented. The compound is intended for research use only and is not approved for human or veterinary use. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. As a naturally occurring amino acid derivative, its toxicity profile is expected to be relatively low, though comprehensive toxicological studies have not been published. For peptides synthesized using this building block, standard toxicological assessments would be performed on the final peptide product rather than on the individual amino acid building block.
|
| References | |
| Additional Infomation |
N-Methyl-L-valine is the optically active form of N-methylvaline with the L-configuration. It is an N-methyl-L-α-amino acid, and also a type of N-methylvaline.
N-Methyl-L-valine (CAS#: 2480-23-1) has a molecular formula of C₆H₁₃NO₂ and a molecular weight of 131.17 g/mol. Its IUPAC name is (S)-3-methyl-2-(methylamino)butyric acid. The compound is also known as H-MeVal-OH, N-Me-Val-OH, and N-Methyl-L-valin. It is highly soluble in water at 100 mg/mL. The N-methylation introduces steric constraints that can significantly alter peptide conformation and biological activity when incorporated into peptides. This compound is a valuable research reagent for peptide synthesis, protein engineering, and structure-activity relationship studies. It is not a drug and has not undergone clinical trials or received regulatory approval for therapeutic use; it is strictly a research reagent. |
| Molecular Formula |
C6H13NO2
|
|---|---|
| Molecular Weight |
131.17
|
| Exact Mass |
131.094
|
| CAS # |
2480-23-1
|
| PubChem CID |
444080
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
206.9±23.0 °C at 760 mmHg
|
| Flash Point |
78.9±22.6 °C
|
| Vapour Pressure |
0.1±0.8 mmHg at 25°C
|
| Index of Refraction |
1.443
|
| LogP |
0.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC([C@H](C(C)C)NC)=O
|
| InChi Key |
AKCRVYNORCOYQT-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)5(7-3)6(8)9/h4-5,7H,1-3H3,(H,8,9)/t5-/m0/s1
|
| Chemical Name |
(2S)-3-methyl-2-(methylamino)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (762.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
